Schlieren (Zurich), Switzerland, June 14, 2018
Kuros announced that today’s General Meeting approved all resolutions proposed by the Board of Directors with a clear majority. In particular, shareholders resolved on the increases and adjustments of the conditional and authorized capital. Joost de Bruijn, Jason Hannon, Scott P. Bruder and Oliver Walker were elected as new members of the Board. A total of 24.4 % of shares were represented at the General Meeting.
The General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2017 and took note of the Reports of the Auditors. Shareholders discharged the Board and the Executive Committee. Shareholders also voted in favor of the proposed appropriation of the Annual Results and approved the compensation for the members of the Board and the Executive Committee. 
Clemens van Blitterswijk was elected as new Chairman as were Leanna Caron, Giacomo Di Nepi, Christian Itin and Gerhard Ries as members of the Board. Shareholders also elected Joost de Bruijn, Jason Hannon, Scott P. Bruder and Oliver Walker as new Board members. Dr. Ries and Mrs. Caron were re-elected as members of the Compensation Committee. Both the current Independent Proxy and the Auditors were confirmed for another one-year term.
Shareholders also resolved on an increase and adjustment of the authorized share capital (to 4,116,464 registered shares with a nominal value of CHF 1.00 each) and the conditional share capital for Employee Participation (to 1,141,258 registered shares with a nominal value of CHF 1.00 each) and corresponding changes to the Articles of Incorporation.
The General Meeting took place at the Company’s headquarters in Schlieren. It was attended by 48 shareholders. 2,009,953 shares or 24.4% of a total 8,232,929 shares were represented.
For further information, please contact:
|
Kuros Biosciences AG |
Media & Investors |
About Kuros Biosciences AG
Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
Kuros Biosciences Ltd, Wagistrasse 25, CH-8952 Schlieren